[미국특허]
Long-acting oxyntomodulin variants and methods of producing same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/24
C07K-014/575
A61K-038/26
A61K-009/00
C07K-014/59
A61K-038/00
출원번호
US-0395441
(2013-04-17)
등록번호
US-9493534
(2016-11-15)
국제출원번호
PCT/IL2013/050332
(2013-04-17)
국제공개번호
WO2013/157002
(2013-10-24)
발명자
/ 주소
Fima, Udi Eyal Eyal
Hershkovitz, Oren
출원인 / 주소
OPKO BIOLOGICS LTD.
대리인 / 주소
Cohen, Mark
인용정보
피인용 횟수 :
0인용 특허 :
80
초록▼
This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor ag
This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of the agonist.
대표청구항▼
1. A CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor agonist and one to five chorionic gonadotropin carboxy terminal peptides (CTP) attached to the amino terminus or carboxy terminus of said agonist, wherein said CTP is from the beta-subunit of human chorionic gonadotropin and com
1. A CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor agonist and one to five chorionic gonadotropin carboxy terminal peptides (CTP) attached to the amino terminus or carboxy terminus of said agonist, wherein said CTP is from the beta-subunit of human chorionic gonadotropin and comprises amino acid positions 1-10 of SEQ ID NO:3. 2. The CTP-modified polypeptide of claim 1, wherein said GLP-1/glucagon receptor agonist is oxyntomodulin. 3. The CTP-modified polypeptide of claim 1, wherein the amino acid sequence of at least one CTP is selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2. 4. The CTP-modified polypeptide of claim 1, wherein at least one CTP is glycosylated or truncated. 5. The CTP-modified polypeptide of claim 1, wherein at least one CTP is attached to said agonist polypeptide via a linker. 6. The CTP-modified polypeptide of claim 5, wherein said linker is a peptide bond. 7. The CTP-modified polypeptide of claim 1, wherein two, three, four or five chorionic gonadotropin carboxy terminal peptides are attached to the carboxy terminus of said agonist. 8. The CTP-modified polypeptide of claim 1, wherein three chorionic gonadotropin carboxy terminal peptides are attached to said agonist, one CTP on the amino terminus and two CTP on the carboxy terminus of said agonist. 9. The CTP-modified polypeptide of claim 1, wherein two chorionic gonadotropin carboxy terminal peptides are attached to said agonist, one CTP on the carboxy terminus and one CTP on the amino terminus of said agonist. 10. The CTP-modified polypeptide of claim 1, wherein two chorionic gonadotropin carboxy terminal peptides are attached to said agonist on the amino terminus of said agonist. 11. The CTP-modified polypeptide of claim 1, wherein said CTP comprises the amino acid sequence set forth in SEQ ID NO: 3. 12. The CTP-modified polypeptide of claim 1, wherein said polypeptide lacks a signal peptide. 13. The CTP-modified polypeptide of claim 1, wherein the amino acid sequence of said CTP-modified polypeptide comprises SEQ ID NO: 9, 15,25, 27,29, amino acids 4-122 of SEQ ID NO: 21, or amino acids 1-119 of SEQ ID NO: 23. 14. The CTP-modified polypeptide of claim 13, wherein said polypeptide is the mature form of said CTP-modified polypeptide and wherein said mature CTP-polypeptide lacks a signal peptide. 15. A pharmaceutical composition comprising the CTP-modified polypeptide of 8. 16. The pharmaceutical composition of claim 15, wherein said GLP 1/glucagon receptor agonist is oxyntomodulin (OXM). 17. A method of producing a CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor agonist and one to five chorionic gonadotropin carboxy terminal peptide (CTP) attached to said agonist, the method comprising the step of attaching one to five chorionic gonadotropin carboxy terminal peptides to the amino terminus or carboxy terminus of said agonist, wherein said CTP is from the beta-subunit of human chorionic gonadotropin and comprises amino acid positions 1-10 of SEQ ID NO:3. 18. The method of claim 17, wherein said GLP-1/glucagon receptor agonist is oxyntomodulin. 19. The method of claim 17, wherein two, three, four, or five chorionic gonadotropin carboxy terminal peptides are attached to the carboxy terminus of said agonist. 20. The method of claim 17, wherein three chorionic gonadotropin carboxy terminal peptides are attached to said agonist, one CTP on the amino terminus and two CTP on the carboxy terminus of said agonist. 21. The method of claim 17, wherein two chorionic gonadotropin carboxy terminal peptides are attached to said agonist, one CTP on the carboxy terminus and one CTP on the amino terminus of said agonist. 22. The method of claim 17, wherein two chorionic gonadotropin carboxy terminal peptides are attached to said agonist on the amino terminus of said agonist. 23. The method of claim 17, wherein the amino acid sequence of said one to five CTP is selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO:2. 24. The method of claim 17, wherein at least one CTP is glycosylated or is truncated. 25. The method of claim 17, wherein at least one CTP is attached to said agonist via a linker. 26. The method of claim 25, wherein said linker is a peptide bond. 27. The method of claim 17, wherein producing said CTP-modified polypeptide extends the biological half-life of said agonist. 28. The method of claim 17, wherein producing said CTP-modified polypeptide improves the area under the curve (AUC) of said agonist. 29. The method of claim 17, wherein producing said CTP-modified polypeptide reduces the dosing frequency of said agonist. 30. The method of claim 17, wherein said CTP comprises the amino acid sequence set forth in SEQ ID NO: 3. 31. The method of claim 17, wherein said CTP-modified polypeptide lacks a signal peptide. 32. The method of claim 17, wherein the amino acid sequence of said CTP-modified polypeptide comprises SEQ ID NO: 9, 15, 25, 27, 29, amino acids 4-122 of SEQ ID NO: 21, or amino acids 1-119 of SEQ ID NO: 23. 33. The method of claim 32, wherein said polypeptide is the mature form of said CTP-modified polypeptide and wherein said mature CTP-polypeptide lacks a signal peptide.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Lee, Dong-Eok; Oh, Myung-Suk; Kim, Ki-Wan; Chung, Bo-Sup; Ha, Byung-Jhip; Park, Ji-Sook, Fusion protein having the enhanced in vivo activity of erythropoietin.
DeFrees, Shawn; Zopf, David A.; Bayer, Robert J.; Hakes, David James; Bowe, Caryn L.; Chen, Xi, Glycopegylation methods and proteins/peptides produced by the methods.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Klima,Horst; Lehmann,Paul; Roeddiger,Ralf; Walter Matsui,Ruth, Method of treating disturbances of iron distribution in inflammatory intestinal diseases.
Martinez, Alexa L; Sherman, Merry R; Saifer, Mark G. P.; Williams, L. David, Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof.
Boime Irving ; Menahem David Ben, Single chain glycoprotein hormones comprising two .beta. and one .alpha. subunits and recombinant production thereof.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-Da (Oakland CA), Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins.
Selden Richard F. ; Borowski Marianne ; Gillispie Frances P. ; Kinoshita Carol M. ; Treco Douglas A. ; Williams Melanie D., Tranfected human cells expressing human .alpha.-galactosidase A protein.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.